1.
Wirach Maek-A-Nantawat,
Supranee Buranapraditkun,
Jettanong Klaewsongkram,
Kiat Ruxrungthum.
Increased Interleukin-17 Production Both in Helper T
Cell Subset Th17 And CD4-Negative T Cells in Human
Immunodeficiency Virus Infection.
Viral
Immunology 2007;
20:66-
2. 75.Asasutjarit R, Lorenzen SI, Sirivichayakul S,
Ruxrungtham
K, Ruktanonchai U, Ritthidej GC. Effect of Solid Lipid
Nanoparticles Formulation Compositions on Their Size, Zeta
Potential and Potential for In Vitro pHIS-HIV-Hugag
Transfection. Pharm Res. 2007 Mar 24.
3. Boom J, Kosters E, Duncombe C, Kerr S,
Hirschel B, Ruxrungtham K, de Mast Q, Kosalaraksa
P,Ulbolyam S,Jupimai T, Ananworanich J;
Staccato
Study Group. Ferritin
levels during
structured treatment interruption of highly active
antiretroviral therapy. HIV Med. 2007Sep;8(6):388-95
4.
Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E,
Hill A, Cooper DA, Phanuphak P, Lang JM, Burger DM, Ruxrungtham K.
Ketoconazole is inferior to
ritonavir as an alternative booster for saquianavir in a once
daily regimen in Thai HIV-1 infected patients. AIDS. 2007 Jul
31; 21(12):1535-9.
5. Madruga JV, Berger D,
McMurchie M, Suter F , Banhegyi D, Ruxrungtham K, Norris
D, Lefebvre E, de Bethune MP, Tomaka F, De Pauw M, Vangeneugden
T, Spinosa-Guzman S; TITAN study group. Efficacy and safety of
darunavir-ritonavir compared with that of lopinavir-ritonavir at
48 weeks in treatment-experienced, HIV-infected patients in
TITAN: aransomised controlled phase III trial. Lancet. 2007 Jul
7:370(9581):49-58.
6. Ananworanich J,
Hirschel B, Sirivichayakul S , Ubolyam S, Jupimai T,
Prasithsirikul W. Chetchotisakd P, Kiertiburanakul S, Munsakul
W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W,
Ruxrungtham K; Staccato Study Team. Absence of resistance
mutations in antiretroviral-naive patients treated with
ritonavir-boosted saquinavir. Antiver Ther.2006;11(5):631-5
7. Boyd MA, Dixit NM,
Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper
DA, Perelson AS, Ruxrungtham K. Viral decay dynamics in
HIV-infected patients receiving ritonavir-boosted saquinavir and
efavirenz with or without enfuvirtide: a randomized, controlled
trial (HIV-NAT 012). J infect Dis. 2006 Nov 1;194(9):1319-22.
Epub2006 Sep 25.
8. Siripassorn K,
Charoenwongse P, Ruxrungtham K. Three suitable antigens
for delayed-type hypersensitivity skin testing in a tropical
country like Thailand. Asian Pac J Allergy Immunol. 2006
Jun-Sep;24(2-3):143-52.
9. Chetchotisakd P,
Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T,
Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K,
Supparatpiho K, Horsakulthai M Chasombat S, Ruxrungtham K; Study Team. High rate multiple drug
resistances in HIV-infected patients failing nonnucleoside
reverse transcriptase AIDS Care (Chic III). 2006 Dec;5(4):152-6
10. Lolekha R, Sirivichayakul
S, Siangphoe U, Pancharoen C, Kaewchana S, Apateerapong W,
Mahanontharit A, Chotpitayasunondh T, Ruxrungtham K,
Phanuphak P, Ananworanich J. Resisance to dual nucleoside
reverse-transcriptase inhibitors in children infected with HIV
clade A/E. Clin infect Dis. 2005 Jan 15;40(2):309-12. 2004 Dec
21.
11. Nuesch R, Ananworanich J,
Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A Cooper D, Lange
J, Phanuphak P, Ruxrungtham K. Development of HIV with
drug resistance after CD4 cell count-guided structured treatment
interruptions in patients treated with highly active
antiretroviral therapy after dual-nucleoside analogue treatment.
Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.
12. Ananworanich J,
Chantaphakul H, Teeratakulpisarn S, Siangphoe U, Ubolyam S,
Chuenyam T,Ungsedhaphan C, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. No effect of interleukin-2 on lgE levels
given in addition to antiretroviral therapy in
HIV-infected adults with CD4 > 300 cells/mm3. Asian Pac J
Allergy Immunol. 2005 Ma; 23(1):23-8.
13. Ananworanich J,
Kosalaraksa P, Hill A, Siangphone U, Bergshoeff A,
Pancharoen C. Engchanil C, Ruxrungtham K, Burger D;
HIV-NAT 017 Study Team. Pharmacokinetics and 24-week
efficacy/safety of dual boosted saquinavir/lopinavier/ritonavir
in nucleoside-pretreated children. Pediatr Infect Dis J. 2005
Oct;24(10):874-9.
14. Ruxrungtham K,
Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet. 2004; 364 :69-82
15. Klaewsongkram J, Ruxrungtham K, Wannakrairot P, Ruangvejvorachai P. Phanupak
P. Eosinophil count in nasal mucosa is more suitable than the
number of ICAM-1 positive nasal epithelial cells to evealuate
the severity of house dust mite-sensitive allergic rhinitis: a
clincal correlation study. Int Arch Allergy Immunol. 2003
Sep;132(1):68-75.
16. Sirivichayakul S, Ruxrungtham K,
Ungsedhapand C, Techasathit W, Ubolyam S,
Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P. Nucleoside
analogue mutations and Q151M in HIV-1 subtype A/E infection
trested with nucleoside reverse transcriptase inhibitors. AIDS.
2003;17:1889-96.
17. Ariyoshi K, Promadej N, Ruxrungtham K, Sutthent R. Toward improved evaluation of
cytotoxic T-lymphocyte (CTL)-inducing HIV vaccines in Thailand.
AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):737-9. No abstract
available.
18. Sirivichayakul S,
Chantratita W, Sutthent R, Ruxrungtham K, Phanuphak P, Oelrichs RB. Survey of reverse
transcriptase from the heterosexual epidemic of human
immunodeficiency virus type 1 CRF01_AE in Thailand from 1990 to
2000. AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1077-81.
19. Nookhai S, Ruxrungtham K,
Phanuphak P, Oelrichs R. Prevalence of
CCR2-641, SDF1-3'A and CCR5-Delta32 alleles in healhy Thais. Eur
J Immunogenet. 200 ; 27:153-7.
20. Suwatanapongched P,
Laohapand P, Ohmoto Y, Ruxrungtham K, interleukin-1beta level in gingival
crevicular fluid of patients with active periodontitis, Asian
Pac J Allergy Immunol. 2000 Dec,18(4):201-7.
21. Wongtim S, Silachamroon U,
Ruxrungtham K, Udompanich V, Limthongkul S, Charoenlap P,
Nuchprayoon C. interferon gamma for diagnosing tuberculous
pleural effusions, Thorax. 1999 Wct;54(10):921-4.
22. Ruxrungtham K, Boone E, Ford H Jr, Driscoll JS, Davey RT Jr,
Lane HC. Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine
against human immunodeficiency virus type 1 infection in
hu-PBL-SCID mice. Antimicrob Agents Chemother. 1996
Wct;40(10):2369-74.
